The Burlingame, CA-based company said it plans to start clinical trials evaluating the wrist-worn neuromodulation therapy Cala Trio device in patients with Parkinson’s disease by the end of 2020. Study participants will be able to use the device from home as indicated in the study with telemedicine visits with neurologists throughout the study.
Cala Trio has been FDA-cleared for treating essential tremors and is available in the US by prescription